Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Does ROZANOLIXIZUMAB Cause Therapeutic product effect incomplete? 13 Reports in FDA Database

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now

According to the FDA Adverse Event Reporting System (FAERS), 13 reports of Therapeutic product effect incomplete have been filed in association with ROZANOLIXIZUMAB (RYSTIGGO). This represents 4.3% of all adverse event reports for ROZANOLIXIZUMAB.

13
Reports of Therapeutic product effect incomplete with ROZANOLIXIZUMAB
4.3%
of all ROZANOLIXIZUMAB reports
0
Deaths
2
Hospitalizations

How Dangerous Is Therapeutic product effect incomplete From ROZANOLIXIZUMAB?

Of the 13 reports, 2 (15.4%) required hospitalization, and 1 (7.7%) were considered life-threatening.

Is Therapeutic product effect incomplete Listed in the Official Label?

This adverse event is not currently listed in the official FDA drug label for ROZANOLIXIZUMAB. However, 13 reports have been filed with the FAERS database.

What Other Side Effects Does ROZANOLIXIZUMAB Cause?

Myasthenia gravis (158) Headache (64) Drug ineffective (54) Diarrhoea (41) Asthenia (36) Fatigue (34) Dyspnoea (29) Nausea (25) Fall (22) Therapeutic response shortened (22)

What Other Drugs Cause Therapeutic product effect incomplete?

ALBUTEROL (8,496) ADALIMUMAB (6,986) PREDNISONE (6,709) METHOTREXATE (6,037) TOFACITINIB (4,914) SECUKINUMAB (4,661) BUDESONIDE\FORMOTEROL (4,392) TIOTROPIUM (4,327) MEPOLIZUMAB (4,106) ETANERCEPT (3,961)

Which ROZANOLIXIZUMAB Alternatives Have Lower Therapeutic product effect incomplete Risk?

ROZANOLIXIZUMAB vs ROZANOLIXIZUMAB-NOLI ROZANOLIXIZUMAB vs RUBIDIUM RB-82 ROZANOLIXIZUMAB vs RUCAPARIB ROZANOLIXIZUMAB vs RUCAPARIB CAMSYLATE ROZANOLIXIZUMAB vs RUFINAMIDE

Related Pages

ROZANOLIXIZUMAB Full Profile All Therapeutic product effect incomplete Reports All Drugs Causing Therapeutic product effect incomplete ROZANOLIXIZUMAB Demographics